Clinical Trial Update: Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) [Phase 3]

View source ↗

Summary

A Phase 3 trial (DeCIDE) evaluated docetaxel-based chemotherapy with or without induction chemotherapy to reduce events in head and neck cancers, including canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngeal Cancer
• Nasal Cavity Cancer
• Oral Cavity Cancer
• Pharyngeal Cancer
• Sinonasal Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: University of Chicago | Conditions: Cancer of the Pharynx, Cancer of the Larynx | Phase 3 | Status: COMPLETED | Results posted: 2018-04-09